Friday, July 10, 2026

pharma · Primary Biliary Cirrhosis · Gastric Intestinal Metaplasia

Xijing Hospital of

Xijing Hospital of clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
2
Drugs
2
Patents
0
Intelligence · Clinical Programs

Xijing Hospital of projects

2 ClinicalTrials.gov programs sponsored by Xijing Hospital of.

Xijing Hospital of has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Fenofibrate

    Xijing Hospital of Digestive Diseases

    Primary Biliary Cirrhosis

    phase 3 small molecule active

    1 trial
  2. Metformin

    Xijing Hospital of Digestive Diseases

    Gastric Intestinal Metaplasia

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Xijing Hospital of have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.